EPAS1 Antikörper (AA 535-631)

Produktnummer ABIN534071

Produktdetails anti-EPAS1 Antikörper

Target: EPAS1 (Endothelial PAS Domain Protein 1 (EPAS1))

Bindungsspezifität: AA 535-631

Reaktivität: Human

Wirt: Maus

Klonalität: Monoklonal

Konjugat: Dieser EPAS1 Antikörper ist unkonjugiert

Applikation: Western Blotting (WB), ELISA, Flow Cytometry (FACS), Immunohistochemistry (Paraffin-embedded Sections) (IHC (p))

Verwendungszweck: Mouse monoclonal antibody raised against partial recombinant EPAS1.

Spezifität: This antibody is specific to HIF-2 alpha and does not cross-react with HIF-1 alpha.

Kreuzreaktivität: Human, Maus, Ratte

Immunogen: Recombinant protein corresponding to amino acids 535-631 of human EPAS1.

Klon: Ep190b

Isotyp: IgG1

Anwendungsinformationen

Applikationshinweise: ELISA (1:1000)
Flow Cytometry (1 μg/mL)
Immunohistochemistry (Formalin/PFA-fixed paraffin-embedded sections) (1:150-1:300)
Western Blot (1:500)
The optimal working dilution should be determined by the end user.

Beschränkungen: Nur für Forschungszwecke einsetzbar

Handhabung

Format: Liquid

Buffer: In PBS (0.09 % sodium azide)

Konservierungsmittel: Sodium azide

Vorsichtsmaßnahmen: This product contains Sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.

Lagerung: -20 °C,-80 °C

Informationen zur Lagerung: Store at -20°C or -80°C.
Aliquot to avoid repeated freezing and thawing.

Referenzen für anti-EPAS1 Antikörper (ABIN534071)

Chintalapudi, Markiewicz, Kose, Dammai, Champion, Hoda, Trojanowska, Hsu: "Cyr61/CCN1 and CTGF/CCN2 mediate the proangiogenic activity of VHL-mutant renal carcinoma cells." in: Carcinogenesis, Vol. 29, Issue 4, pp. 696-703, (2008) (PubMed).

Kubo, Sugita, Shimose, Matsuo, Arihiro, Ochi: "Expression of hypoxia-inducible factor-1alpha and its relationship to tumour angiogenesis and cell proliferation in cartilage tumours." in: The Journal of bone and joint surgery. British volume, Vol. 90, Issue 3, pp. 364-70, (2008) (PubMed).

Bernhardt, Wiesener, Weidemann, Schmitt, Weichert, Lechler, Campean, Ong, Willam, Gretz, Eckardt: "Involvement of hypoxia-inducible transcription factors in polycystic kidney disease." in: The American journal of pathology, Vol. 170, Issue 3, pp. 830-42, (2007) (PubMed).

Sutphin, Chan, Li, Turcotte, Krieg, Giaccia: "Targeting the loss of the von Hippel-Lindau tumor suppressor gene in renal cell carcinoma cells." in: Cancer research, Vol. 67, Issue 12, pp. 5896-905, (2007) (PubMed).

Details zu EPAS1

Target: EPAS1 (Endothelial PAS Domain Protein 1 (EPAS1))

Andere Bezeichnung: HIF2A / HIF2 alpha (EPAS1 Produkte)

Synonyme: EPAS1 antikoerper, ECYT4 antikoerper, HIF2A antikoerper, HLF antikoerper, MOP2 antikoerper, PASD2 antikoerper, bHLHe73 antikoerper, HIF-2alpha antikoerper, HRF antikoerper, Hif2a antikoerper, bhlhe73 antikoerper, ecyt4 antikoerper, hif2 antikoerper, hif2a antikoerper, hif2alpha antikoerper, hlf antikoerper, mop2 antikoerper, pasd2 antikoerper, EPAS antikoerper, EPAS-1 antikoerper, endothelial PAS domain protein 1 antikoerper, endothelial PAS domain protein 1 L homeolog antikoerper, EPAS1 antikoerper, epas1 antikoerper, Epas1 antikoerper, epas1.L antikoerper

Gen-ID: 2034

Pathways: Signaling Events mediated by VEGFR1 and VEGFR2, Warburg Effekt